Skip to main content
OpenTrials
Completed

NCT Number: NCT06377007

Refractive Outcomes and Ocular Biometry of Two Swept-Source Optical Coherence Tomography-Based Biometers With Segmental or Equivalent Refractive Indices (ORION)

This prospective, single-centre, randomized, parallel-group comparative clinical study evaluated the refractive prediction accuracy of two swept-source optical coherence tomography (SS-OCT) biometers in a Thai cataract surgery cohort. The ARGOS biometer applies segmental refractive indices to individual ocular segments, whereas the IOLMaster 700 applies an equivalent refractive index to the whole eye. Each device is conventionally paired with a different keratometry-formula combination: ARGOS with the standard Barrett Universal II (Barrett UII K), and IOLMaster 700 with the Barrett Universal II using total keratometry (Barrett UII TK). The study compared these two device-formula pairings as they are used in routine clinical practice. Both biometers were performed on every eye on the same day, enabling a within-subject paired comparison of biometric agreement and refractive prediction error at one month after phacoemulsification cataract surgery with implantation of a TECNIS Monofocal one-piece IOL (model GCB00V)

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Walailak University

Nakhon Si Thammarat, Changwat Nakhon Si Thammarat, 80160, Thailand

About this study

One hundred and forty-four eyes of 144 consecutive Thai cataract surgery patients aged 40-90 years presenting with visually significant age-related cataract were enrolled at the Ophthalmology Service, Walailak University Hospital between May 2024 and December 2024. Participants underwent preoperative biometric measurement on the same day with both the ARGOS (software version A2.4; Movu, Inc., a Santec company; distributed by Alcon Laboratories) and the IOLMaster 700 (software version 1.90.10; Carl Zeiss Meditec AG) by a single experienced operator. Participants were randomized 1:1 between two IOL-selection arms using a computer-generated allocation sequence (Research Randomizer, blocks of 12): Group 1 used the IOLMaster 700 with the Barrett Universal II TK formula for IOL power selection, and Group 2 used the ARGOS with the standard Barrett Universal II K formula. Allocation was concealed from the enrolling surgeon until completion of preoperative biometry. Participants were masked to the device-formula arm. All cataract surgeries were performed by four experienced surgeons (in approximately equal numbers) using a standardized phacoemulsification technique with in-the-bag implantation of the TECNIS Monofocal one-piece IOL (model GCB00V; Johnson & Johnson Vision). The primary outcome was mean absolute prediction error (MAE) at one month postoperatively, assessed by a masked refractionist using subjective manifest refraction. Secondary outcomes were median absolute prediction error and the proportion of eyes within ±0.25 D and ±0.50 D of target refraction. One eye per patient was enrolled. The study was registered prospectively as a non-inferiority trial; the implemented analysis is reported as a within-subject paired comparative analysis with descriptive accuracy thresholds rather than as a formal non-inferiority hypothesis test (CONSORT item 3b). The total enrolled sample was 144 patients; within-subject paired analyses included 138 eyes with complete data for both devices.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 40-90 years presenting with visually significant age-related cataract scheduled for elective phacoemulsification with implantation of a TECNIS Monofocal one-piece IOL (model GCB00V).

Exclusion criteria

  • Corneal astigmatism greater than 1.00 D on either device
  • Central corneal thickness outside 490-600 µm
  • Severe dry eye precluding reliable keratometry
  • Rigid or soft contact lens wear within 2 months prior to evaluation
  • Previous corneal refractive surgery or other corneal pathology
  • Prior intraocular surgery (other than uneventful cataract surgery in the fellow eye)
  • Clinically significant retinal pathology potentially affecting refractive outcome (e.g., epiretinal membrane, diabetic macular edema, advanced age-related macular degeneration)
  • Intraoperative complications including posterior capsule rupture, vitreous loss, or zonular dehiscence
  • Dense cataract that does not allow measurements with optical biometry
  • Inability to attend follow-up

Treatment and study plan

IOLMaster 700 (Carl Zeiss Meditec AG)

Device

Preoperative biometric measurement using the IOLMaster 700 (software version 1.90.10). IOL power was calculated using the Barrett Universal II TK formula and used for power selection in this arm.

ARGOS (Movu/Santec; distributed by Alcon)

Device

Preoperative biometric measurement using the ARGOS (software version A2.4). IOL power was calculated using the Barrett Universal II K formula and used for power selection in this arm.

Primary outcomes

  1. Mean absolute prediction error

    Time frame: 4 weeks

    Mean absolute prediction error determining by the absolute disparity between the predicted spherical equivalent refraction derived from preoperative planning and the actual measured spherical equivalent refraction (manifest) from both devices (IOLMaster 700 and Argos)

Secondary outcomes

  1. Proportion of eyes with absolute prediction error ≤ 0.25 D

    Time frame: 4 weeks

    Percentage of eyes in which the absolute prediction error (|measured SE - predicted SE|) was within ±0.25 D of the target refraction at one month postoperatively, for each device-formula pairing.

  2. Median absolute prediction error

    Time frame: 4 weeks

    Median of the absolute differences between predicted spherical equivalent refraction (derived from preoperative biometry and IOL formula) and the actual measured spherical equivalent (manifest refraction) at one month postoperatively, for both devices (IOLMaster 700 with Barrett UII TK and ARGOS with Barrett UII K)

  3. Proportion of eyes within ±0.50 D of target refraction

    Time frame: 4 weeks

    Percentage of eyes in which the absolute prediction error was within ±0.50 D of the target refraction at one month postoperatively, for each device-formula pairing.

Sponsors and collaborators

Lead sponsor

Walailak University

Other

Registry information

Official study title

Refractive Outcomes and Ocular Biometry of Two Swept-Source Optical Coherence Tomography-Based Biometers With Segmental or Equivalent Refractive Indices (ORION): A Non-Inferiority Randomized Clinical Trials

Acronym: ORION

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 22, 2024
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.